<DOC>
	<DOCNO>NCT01068717</DOCNO>
	<brief_summary>To demonstrate bioequivalence 2.5-mg saxagliptin/500-mg metformin fixed-dose combination ( FDC ) tablet 2.5-mg saxagliptin ( Onglyza ) 500-mg metformin ( Glucophage , market Canada Sanofi-Aventis ) tablet coadministered healthy participant fast fed state .</brief_summary>
	<brief_title>Bioequivalence Study 2.5-mg Saxagliptin 500-mg Glucophage Tablets Fixed-dose Combination Tablet Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman , age 18 55 year , inclusive Healthy participant determine lack clinically significant deviation normal medical history , physical examination , electrocardiogram , clinical laboratory determination Body Mass Index 18 32 kg/m^2 , inclusive Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Any major surgery within 4 week study drug administration History allergy DPP4 inhibitor related compound History allergy intolerance metformin similar act agent Previous exposure saxagliptin Exposure metformin within 3 month pervious study drug administration Estimated creatinine clearance &lt; 80 mL/min use Cockcroft Gault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>